ServiceNow Strategic Portfolio Management for Life Sciences and Pharma

Strategic Portfolio Management in life sciences and pharma means allocating shared research and development capacity across drug programmes so that leadership can weigh expected return against risk at each stage. This page covers what the portfolio is for, which items belong in it, how stage gates work and where shared capacity breaks down.

Portfolio Management for Drug Development

Life Sciences and Pharma organisations manage hundreds of research and development programmes simultaneously: early-stage research, clinical trials, regulatory submissions, and post-market surveillance. Each programme requires significant investment, uncertain return, and extended timelines before commercialisation. Strategic Portfolio Management helps leadership allocate resources to programmes with the highest potential return and manage risk across the portfolio.

Programme Categorisation and Lifecycle Stages

Drug development follows defined stages from basic research through Phase III clinical trials, regulatory approval, and commercialisation. Early research programmes are high-risk, high-reward: most fail but successful ones can become blockbuster drugs. Late-stage programmes have lower technical risk but higher development cost and regulatory risk. Create portfolio categories reflecting your development stages and tailor governance to each.

Include research collaborations and in-licensed programmes in your portfolio alongside internal programmes. Track them with the same rigour as internal programmes so you have complete visibility of R&D investment. Some external programmes may use different metrics or governance, but they still consume resources and compete for management attention.

Demand Management and Prioritisation

Scientists and research teams always want to start new programmes. Without disciplined demand management, organisations start too many programmes, spreading resources thin and completing none of them. Establish a request process where programme proposals are evaluated against strategic priorities, resource availability, and expected return. Prioritise ruthlessly, funding only programmes with clear strategic value.

Use portfolio models to evaluate new programme proposals: how does this programme align with our strategic direction, what is the probability of success, what is the expected return if successful, how much will it cost to complete? Compare proposals on these criteria and rank them. Fund programmes in priority order until resources are exhausted.

Resource Allocation and Capacity Planning

R&D capacity is finite: limited scientist availability, laboratory space, and budget. Use Strategic Portfolio Management to allocate capacity to programmes by priority. Track resource utilisation by programme so leaders understand where effort is concentrated. If top-priority programmes are under-resourced and low-priority programmes are consuming resources, rebalance allocations.

Plan resource needs for the coming planning horizon, based on programme schedules. If multiple programmes enter clinical trials simultaneously, resource demand spikes. Anticipate spikes and plan hiring or contracting to meet demand without burnout. Use portfolio data to guide headcount planning.

Risk Management Across the Portfolio

Individual programmes are risky; clinical trial failure is common. Portfolio risk is managed by diversifying across multiple programmes in different therapeutic areas and at different development stages. Portfolio dashboards show mix of programmes by therapeutic area, development stage, and risk level. If too much portfolio value sits in one therapeutic area or late-stage programmes, rebalance to reduce risk.

Track programme risks: technology risk, clinical risk, regulatory risk, market risk. When risks materialise, programmes may fail. Have contingency plans: if a lead programme fails, which backup programmes will be accelerated? How will resources be redeployed? These decisions are easier with portfolio visibility than when programmes are managed individually.

Regulatory and Compliance Considerations

Drug development is heavily regulated. Programmes must meet regulatory standards, submit required documentation, and comply with clinical trial regulations. Compliance teams must confirm specific requirements for your operations and therapeutics. Build compliance requirements into portfolio tracking so programmes cannot proceed without required oversight.

Use portfolio visibility to ensure regulatory and compliance expertise is allocated to critical programmes. Do not let compliance be an afterthought; build it in from the start of each programme.

Commercial Readiness and Launch Planning

As programmes progress toward approval, commercial planning begins: manufacturing scale-up, supply chain setup, market access strategy, promotional planning. Strategic Portfolio Management can track commercial readiness alongside development progress. When a programme approaches launch, commercial teams need resources and attention. Portfolio visibility ensures commercial work is not neglected until too late.

Post-Market Surveillance and Lifecycle Management

After regulatory approval, ongoing surveillance is required to monitor safety and efficacy. If new safety signals emerge, programmes may be constrained or withdrawn. Lifecycle management includes line extensions (new formulations, dosages, indications) and eventual off-patent replacement with next-generation products. Portfolio management extends beyond development into the full product lifecycle.

Portfolio Reporting and Leadership Visibility

Executives need high-level visibility of the programme portfolio: how many programmes are in each development stage, what is the total portfolio investment, what is the expected return, how concentrated is portfolio risk? Use dashboards to make portfolio health visible monthly or quarterly. When leadership can see portfolio composition and trends, they can make informed decisions about resource allocation and strategic direction.

Deciding what the portfolio is for before loading any programs

A research portfolio office often inherits a list of programs that were started for good reasons at different times, under different sponsors, with different definitions of success. Loading that list into Strategic Portfolio Management without first agreeing what the portfolio is for produces a dashboard that looks complete and answers no useful question. This section is for portfolio office leads and R&D operations directors who are designing the structure, and who need the structure to still make sense once the first stage gate meeting has happened.

The first decision is scope. A portfolio in this context is a set of programs that compete for the same scarce resources and are reviewed by the same leadership forum. Individual experiments, lab bookings and manuscript work often sit below that level. Putting them in the portfolio creates noise, and taking a single trial program out of it hides the cost of the trial. Write the boundary down, test it on three real examples, and revise it before the rest of the design depends on it.

Which items belong in the portfolio and which stay in the R&D system

The aim is to keep the portfolio at the level where leadership makes trade-offs. Once a study-level detail enters the portfolio, the program-level comparison becomes a comparison of paperwork.

Setting stage gates that a portfolio committee can apply consistently

Stage gates often fail when the criteria are written as aspirations. A useful gate states what evidence must exist before a program moves forward, who judges it, and what the committee will do if the evidence is missing. Work through the sequence below for each development stage in use.

1. Name the decision the gate supports, such as continue funding, widen scope, or stop. A gate that cannot end in a stop is not a gate.
2. List the evidence required at that gate. Keep it to items a program team can produce without special pleading, such as a revised target product profile, an updated development cost estimate and a risk register extract.
3. Assign a single accountable reviewer for each evidence item, not a group.
4. Agree the response to missing evidence in advance. Options include deferring the decision, funding a limited evidence-gathering step, or closing the program.
5. Record the decision, its reasoning and the conditions attached to it in the portfolio record, so later reviews can see why a program continued.

Capacity is where the portfolio view often breaks

Scientists, bioinformatics support and pilot-plant time are shared across programs, and many portfolio tools show them as separate allocations. The same person can appear as fully committed on three programs and nobody sees the overlap until a milestone slips. Build the resource model around named roles or teams rather than individuals where confidentiality allows, and reconcile allocations monthly against actual time recorded in the operational systems. Where a program depends on a single specialist, mark that dependency explicitly so the committee can see the concentration risk before it becomes a delay.

Signs the portfolio is helping decisions

A portfolio view earns its place when leaders change a decision because of it. Check whether stop decisions are being taken on time, whether programs that were stopped have released their resources, and whether reallocations between programs are recorded with a reason. Cycle time for gate decisions is useful, provided it is read as a signal of how the committee works rather than as a target to reduce.

Can one scientist’s time be shared across programs in the portfolio?

Yes, but only if each allocation is recorded as a percentage of a single person or role, and the sum is checked. The portfolio should show when allocations exceed available capacity, and the committee should decide which program gives way.

How should a stopped program be recorded?

Keep the program record, change its status to stopped with the decision date and reason, and release its allocated resources in the same update. Leaving the allocation in place makes the capacity view look full when it is not, which distorts the next funding round.

Does the portfolio tool replace the project management tool used by research teams?

No. Research teams need to plan experiments, track tasks and manage protocols in tools suited to that work. The portfolio holds the program-level view that leadership needs. Feeding milestones from the team tool into the portfolio, rather than asking teams to maintain two copies, keeps the effort proportionate.

How do partnerships fit the same stage gates?

Use the same gate structure, and add a field for the partner’s contribution and the terms that could change the decision. A partnered program that is judged on different criteria from internal ones will be hard to compare when the committee decides where to put the next unit of funding.

For help with the design, a ServiceNow specialist can review your gate model.

Related guides: ServiceNow Strategic Portfolio and Demand Intake and ServiceNow Service Portfolio: Rationalize What You Operate.